Fig. 7: Activity of BLU-954 to EGFR mutants expressing Ba/F3 cells. | npj Precision Oncology

Fig. 7: Activity of BLU-954 to EGFR mutants expressing Ba/F3 cells.

From: A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer

Fig. 7

a–c The selectivity of BLU-954 and combination treatment with panitumumab (10 µg/ml) using the indicated Ba/F3 parental or EGFR mutants expressing Ba/F3 cells. Cells were treated with each drug for 72 h. d IC50 values were calculated from the cell viability assay data in (a–c). Results are presented as mean ± SD.

Back to article page